Scientific Advisory Board Agreement between Regen Biopharma Inc. and Stefano Bertuzzi, Ph.D.
Regen Biopharma Inc. appoints Dr. Stefano Bertuzzi to its Scientific Advisory Board to review research strategies and projects, particularly in immune- and stem cell therapy. Dr. Bertuzzi will participate in monthly conference calls and may attend annual meetings, with related expenses covered by Regen. As compensation, he will receive 100,000 shares of Series A Preferred stock, with the possibility of additional shares upon annual renewal. Any separate consulting work will be negotiated independently. The agreement may be renewed each year by mutual consent.
Exhibit 10.7
October 14, 2015
Stefano Bertuzzi, Ph.D.
American Society for Cell biology
8120 Woodmont Avenue, Suite 750
Bethesda MD 20814-2762
Dear Dr. Bertuzzi
Thank you so much for your willingness to join the Scientific Advisory Board of Regen Biopharma Inc. the function of the Scientific Advisory Board is to review research strategy and projects that Regen Biopharma Inc.may undertake and help identify those projects which may lead to future developments and clinical treatments in the fields of immune- and stem cell therapy. Other areas may be pursued as well, with advice from this SAB.
In consideration for your efforts, you will receive 100,000 shares of Regen Biopharma Series A Preferred stock. Regen’s common stock currently trades on the OTC Bulletin Board (OTCBB:RGBP). The 100,000 Series A Preferred shares are consideration for participating in telephonic conference calls and reviewing scientific strategy and data. It is anticipated that the frequency and timing of such calls will be approximately one call every month. Should we request an annual face to face meeting, expenses will be paid by Regen Biopharma inc. for any out of pocket expenses associated with the meeting.
Additionally, this agreement may be renewed by mutual consent each year on its anniversary date. The compensation on renewal will be another payment of 100,000 Series A preferred stock in Regen on each anniversary that this contract is renewed by the Company.
It is anticipated that members of the Scientific Advisory Board will potentially serve as primary research consultants to the Company as such projects are undertaken. Compensation for such projects will be negotiated separately on a case-by-case basis between the Company and the consultant.
Thank you again for your participation in this exciting initiative.
/s/ Harry Lander
Harry M. Lander
President
